Senores Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	585.6	314.5	84.33	9.91
Depreciation & Amortization	168.1	94.6	3.69	1.42
Other Amortization	0.3	5.6	14.1	5.63
Other Operating Activities	131.1	-11.2	33.19	3.89
Change in Accounts Receivable	-118.8	-571.1	-24.74	-194
Change in Inventory	-192.6	-10.4	-1.42	-26.44
Change in Accounts Payable	-457.9	509	64.46	70.07
Change in Other Net Operating Assets	-575	-588	-184.4	25.05
Operating Cash Flow	-459.2	-257	-10.79	-104.47
Capital Expenditures	-1,575	-518.3	-472.77	-106.82
Cash Acquisitions	-36.9	-32.9	-	-
Investment in Securities	-2,758	-	-10.49	-139.52
Other Investing Activities	71.6	4.7	0.39	1.94
Investing Cash Flow	-4,295	-542.3	-482.87	-244.4
Short-Term Debt Issued	922	580.4	290.4	15.06
Long-Term Debt Issued	295.4	31.7	175.46	89.93
Total Debt Issued	1,217	612.1	465.86	104.99
Long-Term Debt Repaid	-	-13.7	-	-0.87
Net Debt Issued (Repaid)	1,217	598.4	465.86	104.12
Issuance of Common Stock	4,718	369.9	26.82	240.21
Other Financing Activities	-203.7	-98.5	-30.17	20.29
Financing Cash Flow	5,731	869.8	462.51	364.62
Miscellaneous Cash Flow Adjustments	-	5	-	-
Net Cash Flow	977.3	75.5	-31.15	15.75
Free Cash Flow	-2,034	-775.3	-483.56	-211.29
Free Cash Flow Margin	-51.08%	-36.14%	-136.84%	-149.11%
Free Cash Flow Per Share	-55.94	-30.09	-38.12	-38.53
Cash Interest Paid	203.6	85	18.37	5.1
Cash Income Tax Paid	91.7	24.9	14.53	1.41
Levered Free Cash Flow	-2,414	-1,035	-543.86	-
Unlevered Free Cash Flow	-2,287	-982	-532.38	-
Change in Working Capital	-1,344	-660.5	-146.1	-125.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.